← SynDRA
BEMPEDOIC ACID
SynDRA canonical compound SYN0038273 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | ACLY |
|---|
| Mechanism of action | AMPK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- ACLY INHIBITOR
- ATP-citrate synthase inhibitor
- AMPK inhibitor
Drug classes
- Antimetabolites
- Enzyme Inhibitors
- Hypoglycemic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Adenosine Triphosphate-Citrate Lyase Inhibitor
- Adenosine Triphosphate-Citrate Lyase Inhibitors
ATC classes
- C10A · LIPID MODIFYING AGENTS, PLAIN
- LIPID MODIFYING AGENTS, COMBINATIONS
Cross-references
Synonyms
- ETC-1002
- ESP-55016
- nexletol
- nilemdo
- Acide bempedoique
- Acido bempedoico
- ETC1002
- Bempedoic acid component of nexlizet
- Nexletol
- Nilemdo
- ETC 1002
- 8-Hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
- ESP 55016
- UNII-1EJ6Z6Q368
- 1EJ6Z6Q368
- Bempedoate
- Bempedoic acid [USAN:INN]
- Bempedoic acid (USAN/INN)
- SCHEMBL185768
- GTPL8321
- CHEMBL3545313
- HYHMLYSLQUKXKP-UHFFFAOYSA-N
- EX-A1243
- ZINC3948738
- BCP16083
- s7953
- AKOS027439916
- CS-3952
- DB11936
- AK499358
- AC-29040
- AS-49804
- HY-12357
- Bempedoic Acid(ETC-1002;ESP-55016)
- D10691
- Pentadecanedioic acid, 8-hydroxy-2,2,14,14-tetramethyl-
- NEXLIZET COMPONENT BEMPEDOIC ACID
Reported adverse events
- Gout
- Pain in extremity
- Abdominal pain
- Back pain
- Hypersensitivity
- Muscle spasms
- Arthralgia
- Bronchitis
- Cholelithiasis
- Fatigue
- Upper respiratory tract infection
- Renal impairment
Look up BEMPEDOIC ACID in the interactive SynDRA portal →